Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Thymosin-alpha 1 Used for Adjuvant Treatment After Radical Resection of High-risk Stage II and Stage III Colorectal Cancer

NCT05086614 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05086614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05086614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Thymosin-alpha 1 Used for Adjuvant Treatment After Radical Resection of High-risk Stage II and Stage III Colorectal Cancer
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Recruiting
Start date
April 1, 2021
Completion date
March 31, 2027
Enrollment
2,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii colorectal cancer, stage iii colorectal cancer